These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Listed as ongoing, but also has a completion date||2009-016996-31||A Randomized, Multicenter, Double-Blind, Placebo–Controlled, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of USL255 as Adjunctive Therapy in Patients with Refractory Partial-Onse...||2012-12-18||bad-data|
|Not reported||2009-017904-95||Estudio abierto de extensión para evaluar la seguridad de USL255 como terapia adyuvante en pacientes con crisis de inicio parcial refractarias que habían participado en el P09-004, un estudio en fase ...||2014-03-13||due-trials|
|Not reported Terminated||2011-001318-32||A Randomized, Double-Blind, Placebo-Controlled Study of||2017-02-22||due-trials|
|Not reported Terminated||2011-004109-25||An Open-Label Safety Study of USL261 in the Outpatient Treatment of Subjects with Seizure Clusters||2017-02-22||due-trials|
|Reported results||2014-003961-49||A Randomized, Double-Blind, Placebo Controlled Trial Examining the Safety and Efficacy of Midazolam Intranasal Spray (USL261) for the Treatment of Intermittent Bouts of Increased Seizure Activity in t...||2016-08-26||due-trials|
|Exempt Terminated||2015-004214-14||A Phase 1/2 Dose-escalation of USL311 as Single Agent and in Combination with Lomustine (CCNU) in Subjects with Advanced Solid Tumors, with Subsequent Single Agent and Combination Phase 2 Cohorts for ...||not-yet-due|